QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)
Centre Hospitalier Universitaire de Saint Etienne
196 participants
Jul 17, 2019
INTERVENTIONAL
Conditions
Summary
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.
Eligibility
Inclusion Criteria4
- Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
- Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
- Social security affiliation
- Signed informed consent
Exclusion Criteria3
- Wardship patient and curatorial patient
- Patient unable to understand or sign the protocol
- Colectomy total or partial
Interventions
Two more biopsies in inflammatory zone will be collected.
Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04030676